Insider buy: ProMIS Neurosciences (PMN) CDO acquires 1,629 shares at $15.35

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. Chief Development Officer Johanne Kaplan bought 1,629 common shares in an open-market purchase at $15.35 per share. After this transaction, Kaplan directly owns 3,941 common shares, modestly increasing personal equity exposure to the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaplan Johanne

(Last) (First) (Middle)

PROMIS NEUROSCIENCES INC.

SUITE 200, 1920 YONGE STREET

(Street)

TORONTO A6 M4S 3E2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/19/2026		P		1,629	A	$15.35	3,941	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Max A. Milbury, Attorney in Fact for Johanne Kaplan	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ProMIS Neurosciences (PMN) report on this Form 4?

ProMIS Neurosciences reported that Chief Development Officer Johanne Kaplan purchased 1,629 common shares. The transaction was an open-market purchase at a price of $15.35 per share, increasing Kaplan’s directly held stake in the company.

How many ProMIS Neurosciences (PMN) shares did Johanne Kaplan buy and at what price?

Johanne Kaplan bought 1,629 common shares of ProMIS Neurosciences at $15.35 per share. This open-market purchase reflects the total share amount and price disclosed for the reported non-derivative transaction on the Form 4.

What is Johanne Kaplan’s ProMIS Neurosciences (PMN) share ownership after the transaction?

After the reported trade, Johanne Kaplan directly owns 3,941 common shares of ProMIS Neurosciences. This figure represents her total direct non-derivative holdings following the 1,629-share open-market purchase disclosed in the Form 4 filing.

What role does Johanne Kaplan hold at ProMIS Neurosciences (PMN)?

Johanne Kaplan serves as Chief Development Officer at ProMIS Neurosciences. The Form 4 identifies her as an officer of the company and reports her personal open-market purchase of 1,629 common shares at $15.35 per share.

Was the ProMIS Neurosciences (PMN) insider transaction a buy or a sell?

The transaction was a buy. The Form 4 classifies it as an open-market purchase of 1,629 common shares, with transaction code “P” and direction noted as a net buy, increasing Johanne Kaplan’s directly owned share position.

Is Johanne Kaplan’s ownership in ProMIS Neurosciences (PMN) direct or indirect?

Kaplan’s reported holdings are direct. The Form 4 lists the ownership code as “D” for direct, indicating the 3,941 common shares, including the newly purchased 1,629 shares, are held in her own name rather than through another entity.